Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha-2b plus DNP-modified autologous tumor vaccine in advanced melanoma
ChiCTR-TRC-09000497Phase 3Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2003
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of interferon alfa-2b and M-Vax in melanoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Overall survival, Clinical benefit rate and 3 more. Started Jan 2003; status: completed.
02
Drugs
interferon alfa-2bM-Vax
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR-TRC-09000497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000497.